FDA Approves First Pediatric Heart Valve Designed to Be Expanded as Children Grow
The Autus Size-Adjustable Valve uses synthetic leaflets and can be widened by balloon catheter, which may reduce repeat open-heart surgeries; long-term data are still being collected.
On October 1, the US Food and Drug Administration approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease [1]. Edwards Lifesciences received the approval. The valve was developed by Autus Valve Technologies Inc. [1], which Edwards bought in February 2026 for $128.9 million [4][5].
Congenital heart defects affect about 1 in every 100 births. Citing the CDC, the FDA says pulmonary valve atresia and stenosis together affect about 4,200 babies in the US each year [1]. Children who receive a replacement pulmonary valve face a basic mismatch: a fixed-size valve does not grow with them. According to the FDA, this often means multiple open-heart surgeries during childhood [1]. Valves made from animal tissue also tend to harden and break down faster in children [1].
What Was Approved
The FDA describes the Autus valve as the first heart valve designed to be expanded after surgery [1]. Surgeons can implant it at about 13 millimeters in diameter, a size the agency describes as suited to a toddler or preschool-aged child. It can later be widened in a catheter procedure using a balloon, reaching up to 22 millimeters, which is comparable to an adult pulmonary valve [1].
It is also the first valve approved in the US to use polymeric (synthetic) leaflet material rather than animal tissue, for any indication [1]. The FDA says one-year follow-up data suggest the synthetic leaflets hold up well over time [1].
The device went through premarket approval, the FDA's most stringent review pathway for high-risk devices. It had previously received Breakthrough Device designation [1]. It is also the first pediatric approval from the FDA's Total Product Life Cycle Advisory Program (TAP), a pilot program that offers developers early, ongoing agency engagement [1][6].
Study Design and Limitations
The pivotal study enrolled 62 pediatric patients at 12 US sites, and all had a successful implant procedure [1]. At six-month follow-up, the first 60 patients showed acceptable hemodynamic performance, with no more than mild leakage back through the valve [1].
No patient died, had a stroke, or developed blood clots requiring further treatment or other clot-related complications [1]. Three patients had a fracture in the valve frame. Two had reduced movement of one valve leaflet. None of these events caused symptoms [1].
Edwards reported additional results. It said 100% of patients were free from device-related complications through 30 days, and that no patient needed a valve reintervention through six months [2][3]. Among patients who completed one year of follow-up, the company said all had a right ventricular outflow tract mean gradient of 40 mmHg or less, less than moderate pulmonary regurgitation and no reinterventions [2][3]. The company did not say how many patients have reached one year. Patients will be followed for 10 years [2][4].
Several limitations matter. The cohort is small, and follow-up is short compared with a childhood of growth. The FDA notes that valve performance began to deteriorate in two patients who were starting to outgrow the valve. Both were expanded without invasive surgery, but the agency says "the experience is limited" [1]. The sources reviewed for this article do not describe a control group or name a peer-reviewed publication of the pivotal results. The figures above come from the FDA and from company announcements. One investigator quoted in coverage, Dr. Emile Bacha of NewYork-Presbyterian/Columbia, took part in the pivotal trial [4].
Clinical and Patient Implications
The potential benefit is fewer open-heart operations. CDRH director Dr. Michelle Tarver said the valve "gives doctors the option of far fewer trips to the operating room" [1]. Bacha described it as offering a new way to think about long-term care planning [4]. Whether expansion can reliably delay or replace repeat surgery over many years has not yet been shown. The FDA says longer-term studies are under way to understand the observed risks and to confirm that expansion maintains a functioning valve [1].
Some early coverage has said children will no longer need repeat surgeries [5]. That goes further than the evidence. The FDA's own wording is that the valve may reduce that need [1].
What Comes Next
Implants are continuing outside the pivotal trial. In September, surgeons at C.S. Mott Children's Hospital performed the first Autus implant in a continued-access study [4]. According to Kolaleh Eskandanian, a pediatric device innovation researcher who reports no financial ties to Edwards or Autus, the work began about a decade ago in a Boston Children's Hospital lab and included testing in growing lambs [6]. She argues that the approval exposes gaps in how regulators handle devices for growing patients, including the lack of shared growth models and standardized growth testing [6].
The 10-year follow-up will be the real test. Key questions are how often frame fractures occur, how many expansions a child needs, and whether the polymer leaflets stay durable into adolescence.
This article is for informational purposes only and is not medical advice; readers should consult their clinician about any health concerns.
References
US Food and Drug Administration. "FDA Approves First Heart Valve Designed to Grow with Children." Press announcement, Oct 1, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-heart-valve-designed-grow-children
Diagnostic and Interventional Cardiology (DAIC). "FDA Approves Surgical Pulmonary Valve for Pediatric Patients." Oct 2, 2026. https://www.dicardiology.com/content/fda-approves-surgical-pulmonary-valve-pediatric-patients
Brusco S. "Edwards Wins FDA Approval for Pediatric, Size-Adjustable Pulmonary Valve." Medical Product Outsourcing, Oct 1, 2026. https://www.mpo-mag.com/breaking-news/edwards-wins-fda-approval-for-pediatric-size-adjustable-pulmonary-valve/
Fornell D. "FDA approves first heart valve that grows with children." Cardiovascular Business, Oct 1, 2026 (updated Oct 2). https://cardiovascularbusiness.com/topics/congenital-heart-disease/fda-approves-first-heart-valve-grows-children
Zarev V. "The Double Firsts of Edwards' Autus Approval." Cardiac Wire, Oct 5, 2026. https://cardiacwire.com/the-double-firsts-of-edwards-autus-approval/
Eskandanian K. "A heart valve that grows with children shows what pediatric devices can become." Medical Design & Outsourcing, Oct 2, 2026. https://www.medicaldesignandoutsourcing.com/autus-heart-valve-pediatric-devices-regulatory-eskandian/
